Hematologic Oncology

Dr. William Wierda, from the MD Anderson Cancer Center, Discusses Watchful Waiting in CLL

Treatment of selected cases of localized lymphoma during the second and third trimester was associated with minimal maternal and fetal risk of complications.

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials

The burden of late complications after hematopoietic cell transplantation is high, and these late effects are associated with poor health and decreased functional status.

Dr. Stephen Ansell from the Mayo Clinic in Minnesota Describes Waldenstrom Macroglobulinemia Symptoms

A review of interesting presentations from ASH that will stimulate highly clinically relevant discussion regarding disease management within the realm of the hematologic malignancies.

Dr. William Wierda, from MD Anderson Cancer Center, on Diagnosing Chronic Lymphocytic Leukemia

A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.

Dr. Ruben Mesa from the Mayo Clinic in Arizona Discusses JAK Inhibitors for Myelofibrosis

Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma

Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS

Certain characteristics of patients with CML can affect therapeutic outcomes.

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Dr. Stephen Ansell from the Mayo Clinic Describes Waldenström Macroglobulinemia

Two phase III clinical trials showed that nilotinib continues to demonstrate more favorable molecular response levels in patients with Ph CML than imatinib mesylate.

Dr. Paul Hamlin, from Memorial Sloan-Kettering Cancer Center, Discusses Integrating Brentuximab Vedotin

Dr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Novel therapeutics, including thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade), have revolutionized the treatment of multiple myeloma.

The treatment of diffuse large B-cell lymphoma continues to evolve, as researchers seek to improve upon the current standard of care.

Much has been made of the difficulties companies, investigators, and patient advocates have in providing access to novel therapies.